The Danish National Patient Registry: a review of content, data quality, and research potential
M Schmidt, SAJ Schmidt, JL Sandegaard… - Clinical …, 2015 - Taylor & Francis
Background The Danish National Patient Registry (DNPR) is one of the world's oldest
nationwide hospital registries and is used extensively for research. Many studies have …
nationwide hospital registries and is used extensively for research. Many studies have …
The Danish Civil Registration System as a tool in epidemiology
M Schmidt, L Pedersen, HT Sørensen - European journal of epidemiology, 2014 - Springer
The methodological advances in epidemiology have facilitated the use of the Danish Civil
Registration System (CRS) in ways not previously described systematically. We reviewed …
Registration System (CRS) in ways not previously described systematically. We reviewed …
Structure and function of sulfotransferases
M Negishi, LG Pedersen, E Petrotchenko… - Archives of biochemistry …, 2001 - Elsevier
Sulfotransferases (STs) catalyze the transfer reaction of the sulfate group from the ubiquitous
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to an acceptor group of …
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to an acceptor group of …
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism
J Christensen, TK Grønborg, MJ Sørensen, D Schendel… - Jama, 2013 - jamanetwork.com
Importance Valproate is used for the treatment of epilepsy and other neuropsychological
disorders and may be the only treatment option for women of childbearing potential …
disorders and may be the only treatment option for women of childbearing potential …
[HTML][HTML] Incidence of adenocarcinoma among patients with Barrett's esophagus
F Hvid-Jensen, L Pedersen, AM Drewes… - … England Journal of …, 2011 - Mass Medical Soc
Background Accurate population-based data are needed on the incidence of esophageal
adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus …
adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus …
Derivatives of erythropoietin that are tissue protective but not erythropoietic
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through
interaction with different receptors. We generated receptor subtype–selective ligands …
interaction with different receptors. We generated receptor subtype–selective ligands …
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 …
Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …
progression typically occurs 3–5 years after initial treatment. We assessed the potential …
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings, A Loft, M Hansen, LM Pedersen, T Buhl… - Blood, 2006 - ashpublications.org
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis.
This investigation prospectively assessed the value of positron emission tomography with 2 …
This investigation prospectively assessed the value of positron emission tomography with 2 …
[HTML][HTML] Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus …
PURPOSE: Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit
lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by …
lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by …
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway …
Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after
vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and …
vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and …